A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2011
At a glance
- Drugs SU 014813 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Apr 2011 Planned end date changed from 1 Mar 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.